Clinical trial NCT00258609 - References

Migraine Without Aura Prophylaxis — Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study

Citation(s)

•   Aoki KR
  Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003 Jul-Aug;43 Suppl 1:S9-15. Review.
•   Arezzo JC
  Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S125-32. Review.
•   Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K
  Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci. 2002 Dec 15;205(1):59-63.
•   Blumenfeld AM, Dodick DW, Silberstein SD
  Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004 Apr;22(2):167-75. Review.
•   Borodic GE, Acquadro M, Johnson EA
  Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001 Aug;10(8):1531-44. Review.
•   Brin MF
  Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-68. Review.
•   Caputi CA
  Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release. Headache. 2004 Sep;44(8):837-8.
•   Chankrachang S, Arayawichanont A, Poungvarin N, Nidhinandana S, Boonkongchuen P, Towanabut S, Sithinamsuwan P, Kongsaengdao S
  Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. Headache. 2011 Jan;51(1):52-63. doi: 10.1111/j.1526-4610.2010.01807.x. Epub 2010 Nov 16.
•   Cui M, Khanijou S, Rubino J, Aoki KR
  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33.
•   Durham PL, Cady R, Cady R
  Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004 Jan;44(1):35-42; discussion 42-3.
•   Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW
  Treatment of headache with botulinum toxin A--a review according to evidence-based medicine criteria. Cephalalgia. 2002 Nov;22(9):699-710. Review.
•   Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A
  Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004 Oct;24(10):838-43.
•   Göbel H
  Botulinum toxin in migraine prophylaxis. J Neurol. 2004 Feb;251 Suppl 1:I8-11. Review.
•   Krämer HH, Angerer C, Erbguth F, Schmelz M, Birklein F
  Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol. 2003 Feb;250(2):188-93.
•   Silberstein S, Mathew N, Saper J, Jenkins S
  Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000 Jun;40(6):445-50.
•   Silberstein SD
  Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. Review.
•   Smuts JA, Schultz D, Barnard A
  Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004 Sep;44(8):801-5.
•   Tepper SJ, Bigal ME, Sheftell FD, Rapoport AM
  Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004 Sep;44(8):794-800.
•   Turton K, Chaddock JA, Acharya KR
  Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002 Nov;27(11):552-8. Review.

A 12-week Prospective, Double-blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis.

Details for clinical trial NCT00258609